Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer
Autor: | Henrik Lindman, Päivi Auvinen, Greger Nilsson, Riikka Huovinen, Minna Tanner, Vesa Kataja, Johan Ahlgren, Sanna Kosonen, Outi Lahdenperä, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Kenneth Villman, Heikki Joensuu, Paula Poikonen-Saksela, R. Kokko, Arja Jukkola-Vuorinen, Paul Nyandoto, Jouni Junnila |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
Cancer Research medicine.medical_treatment Triple Negative Breast Neoplasms Docetaxel 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols polycyclic compounds Medicine 030212 general & internal medicine skin and connective tissue diseases Finland Triple-negative breast cancer Original Investigation Middle Aged 3. Good health Treatment Outcome Receptors Estrogen Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Taxoids Fluorouracil Receptors Progesterone therapeutics medicine.drug Epirubicin Adult medicine.medical_specialty Adolescent Bevacizumab Capecitabine Young Adult 03 medical and health sciences Breast cancer Internal medicine Humans neoplasms Cyclophosphamide Aged Sweden Chemotherapy business.industry ta3121 medicine.disease carbohydrates (lipids) Regimen business |
Zdroj: | JAMA Oncology. 3:793 |
ISSN: | 2374-2437 |
Popis: | Importance Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer (TNBC). Objective To investigate the effect of capecitabine on long-term survival outcomes of patients with early breast cancer, particularly in subgroups defined by cancer estrogen receptor (ER) and progesterone receptor (PR) content, and HER2 content (human epidermal growth factor receptor 2). Design, Setting, and Participants This is an exploratory analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Finland and Sweden between January 27, 2004, and May 29, 2007. About half received 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX). Data analysis took place between January 27, 2004, and December 31, 2015. Main Outcomes and Measures Recurrence-free survival (RFS). Results Following random allocation, 747 women received T+CEF, and 753 women received TX+CEX. Five patients were excluded from the intention-to-treat population (3 had overt distant metastases at the time of randomization; 2 withdrew consent). The median age of the remaining 1495 patients was 53 years at the time of study entry; 157 (11%) had axillary node-negative disease; 1142 (76%) had ER-positive cancer; and 282 (19%) had HER2-positive cancer. The median follow-up time after random allocation was 10.3 years. There was no significant difference in RFS or overall survival between the groups (hazard ratio [HR], 0.88; 95% CI, 0.71-1.08; P = .23; and HR, 0.84, 95% CI, 0.66-1.07; P = .15; respectively). Breast cancer-specific survival tended to favor the capecitabine group (HR, 0.79; 95% CI, 0.60-1.04; P = .10). When RFS and survival of the patients were compared within the subgroups defined by cancer steroid hormone receptor status (ER and/or PR positive vs ER and PR negative) and HER2 status (positive vs negative), TX+CEX was more effective than T+CEF in the subset of patients with TNBC (HR, 0.53; 95% CI, 0.31-0.92; P = .02; and HR, 0.55, 95% CI, 0.31-0.96; P = .03; respectively). Conclusions and Relevance Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prolong RFS or survival compared with a regimen that contained only standard agents. Patients with TNBC had favorable survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgroup analysis. Trial Registration clinicaltrials.gov Identifier:NCT00114816 |
Databáze: | OpenAIRE |
Externí odkaz: |